Jazz Pharmaceuticals JAZZ
today announced an underwritten public offering of 5,375,000 of its ordinary
shares held by certain of its existing shareholders. Jazz Pharmaceuticals will
not receive any proceeds from the sale of ordinary shares by the selling
shareholders in the offering, and its total number of ordinary shares
outstanding will not change as a result of the offering.
Barclays Capital Inc. is acting as sole book-running manager and underwriter
in this offering.
A registration statement relating to the shares described above was previously
filed with and has become effective by rule of the Securities and Exchange
Commission ("SEC"). A final prospectus supplement relating to the offering
will be filed with the SEC. Copies of the final prospectus supplement and
related prospectus, when available, may be obtained from Barclays Capital
Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, or by telephone at 1-888-603-5847, or by email at
Barclaysprospectus@broadridge.com. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any
sale of, the shares in any state or other jurisdiction which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem^® (sodium oxybate) oral solution, Erwinaze^® (asparaginase Erwinia
chrysanthemi), Prialt^® (ziconotide) intrathecal infusion, FazaClo^®
(clozapine, USP) HD, FazaClo LD, and Luvox CR^® (fluvoxamine maleate). Outside
of the U.S., Jazz Pharmaceuticals also has a number of products marketed by
its EUSA Pharma division.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in